RecruitingNCT05705531
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Studying Classic Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Robert J Hayashi, MDChildren's Oncology Group
- Intervention
- Archive Sample Retrieval(procedure)
- Enrollment
- 190 enrolled
- Eligibility
- 7 years · All sexes
- Timeline
- 2023 – 2028
Study locations (29)
- USA Health Strada Patient Care Center, Mobile, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Yale University, New Haven, Connecticut, United States
- Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
- Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
- Arnold Palmer Hospital for Children, Orlando, Florida, United States
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Albany Medical Center, Albany, New York, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05705531 on ClinicalTrials.govOther trials for Classic Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07275216Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentCity of Hope Medical Center
- RECRUITINGPHASE2NCT07209059PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaNational Research Center for Hematology, Russia
- RECRUITINGPHASE2NCT06984146Nivo40-AVD for Advanced Classic Hodgkin LymphomaNational Medical Research Radiological Centre of the Ministry of Health of Russia
- RECRUITINGPHASE2NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE1, PHASE2NCT06642792A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaAkeso
- RECRUITINGPHASE2NCT06377540MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07234487Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTSt. Petersburg State Pavlov Medical University